Revenue
FY 2025 · reported

Today's range · Low → High
Explore the business heartbeat, inspect the statements, challenge financial quality, test expectations, and preserve the unknowns before writing a thesis.
Years
10
Quarters
12
Latest FY
2025
Business heartbeat
A compact view of growth, profitability, cash generation, leverage, and ownership. Open the statements for the accounting detail behind each signal.
Revenue
FY 2025 · reported
Operating margin
Operating profit ÷ revenue
Free cash flow
Operating cash flow less capital expenditure
Net debt
Reported debt less cash; check leases and restrictions
Revenue trend
Cash conversion
Volume
Does The Move In Merck Stock Change Anything?
Record Highs Beckon for Big Caps as Small Caps Lag and Deal Flow Builds
QYLG Vs. QDVO: Market Fear Is Good For These Paychecks
Eli Lilly (LLY) As Zepbound And Retatrutide Updates Test Whether More Upside Is Priced In
Eli Lilly (LLY) Posted 48% Revenue Growth. Why Does the Stock Trade Below Its Average Multiple?
Eli Lilly’s Biggest Shareholder Just Filed to Sell $347 Million of Stock
Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
TRex Bio IPO raises $116.7 million, prices at bottom of range
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
Data from Finnhub. Quotes may be delayed up to 15 minutes. Not financial advice.